Biomedical and Biochemical Basis of Neurodegenerative Diseases

Dear Colleagues,

In most brain-related diseases, neurodegeneration has been shown to be the primary pathophysiological alteration, and several different neurological conditions are referred to as neurodegenerative diseases. Memory, cognition, behavior, sensory function, and/or motor function are all negatively impacted by the degeneration of neural networks and the loss of neurons, which are incapable of efficiently renewing themselves because they are terminally differentiated. This leads to the breakdown of the fundamental communication circuitry. An individual may exhibit more than one neurodegenerative disease process, and the protein abnormalities that characterize neurodegenerative disorders might exist before the beginning of clinical symptoms. Currently, diagnostic biomarkers are unavailable, with the exception of rare instances in which the condition may be demonstrated to be caused by a causal genetic mutation. In addition to the diagnosis, the neurodegenerative diseases field needs new clinical, pathological, pharmacological, and genetic research. Instead, the age of onset, the sex of patient, the duration of symptoms, clinical diagnosis, the clinical markers of disease severity, the density and distribution of different pathologic processes, and the pharmacogenetic and pharmacokinetic characteristics of treatment should be investigated to achieve an increasingly better management of individual patients.

This proposed Special Issue aims to collect studies that provide clinical, biochemical, and therapeutic evidence on neurodegenerative diseases. In particular, we welcome original research articles and reviews, including but not limited to the following topics:

• The biochemistry of neurodegenerative diseases.
• The clinical basis of neurodegenerative diseases.
• The genetics of neurodegenerative diseases.
• Genetic influence on drug pharmacokinetics and pharmacodynamics in neurodegenerative diseases.
• Combining therapeutic drug monitoring (TDM) with genetics in neurodegenerative diseases treatment.
• Personalized medicine in neurodegenerative diseases.
• Sex differences in neurodegenerative diseases.

Dr. Sarah Allegra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• neurodegeneration
• personalized medicine
• biomarkers
• diagnosis
• treatment